Help Us Advance Prostate Cancer Care 🎗️
What is the PC RADAR Survey?
Radioligand Therapy (RLT), also known as Lutetium (Lu-177) therapy or peptide receptor radionuclide therapy (PRRT), is an innovative treatment option that can significantly improve outcomes for prostate cancer patients. However, awareness, access, and understanding of this therapy remain uneven across Europe.
SPARC-Europe has launched the Prostate Cancer Radioligand Awareness Research (PC RADAR) initiative to gather insights from patients, healthcare professionals, caregivers, researchers, and other stakeholders. The findings will inform evidence-based policy recommendations aimed at improving knowledge, accessibility, and availability of RLT for prostate cancer.
Who should participate?
We invite:
Prostate cancer patients
Healthcare professionals involved in prostate cancer care
Caregivers and family members
Researchers and other stakeholders in the field
Do you know someone who fits this description? Please share the survey with them and help us spread the word.
Make a difference in the future of prostate cancer care!
Click below to take the survey:
🏥 Patient
🏥Researchers and Caregivers
🧑⚕️ Healthcare Professional
SPARC-Europe would like to express its gratitude to the PC RADAR working group and expert reviewers for their contributions in shaping and validating this survey.
For any questions regarding the survey’s content, objectives, or progress, please contact us at secretariat@sparc-europe.com.